Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026 [Seeking Alpha]
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: Seeking Alpha
SRPT's PMO franchise remains its cash engine, but regulatory reliance on real-world evidence and FDA unpredictability add risk to the investment thesis. Label contraction for Elevidys and margin pressures weigh on near-term outlook, with upside catalysts mostly expected in 2026 from RNA therapeutics data. Maintain a cautious Hold on SRPT due to high risk, regulatory overhangs, and poor near-term visibility; only suitable for risk-tolerant investors. J Studios/DigitalVision via Getty Images Overview Amidst great uncertainty, Sarepta Therapeutics, Inc. SRPT ) is trying to sell certainty to investors, but they aren't buying it. Sarepta's third quarter earnings report sent its stock down ~25%. Beyond Elevidys' Y/Y revenue decline “as a result This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with DuchenneBusiness Wire
- Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1Business Wire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPTPR Newswire
- Is Sarepta Therapeutics a Bargain After Its 82% Drop Over the Last Year? [Yahoo! Finance]Yahoo! Finance
- FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths [Yahoo! Finance Canada]Yahoo! Finance Canada
SRPT
Earnings
- 11/3/25 - Beat
SRPT
Sec Filings
- 12/2/25 - Form 4
- 11/19/25 - Form 4
- 11/14/25 - Form SCHEDULE
- SRPT's page on the SEC website